Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
Qihan FuYiwen ChenDabing HuangChengxiang GuoXiaochen ZhangWenbo XiaoXing XueQi ZhangXiang LiShunliang GaoRisheng QueYan ShenJian WuMin ZhangTingbo LiangTingbo LiangPublished in: Annals of surgical oncology (2023)
The study did not meet its primary endpoint, no clear survival benefit was observed, and the benefit of sintilimab + mFFX for advanced pancreatic cancer was not supported; however, the findings suggest that using this regimen for pancreatic cancer is feasible, has an acceptable safety profile, and leads to an objective response rate of 50%. Trial registration ClinicalTrials.Gov; NCT03977272.